Abdominal Pain Clinical Trial
— LactoFAPOfficial title:
Efficacy of Lactobacillus Reuteri Protectis on Functional Abdominal Pain (FAP) in Children 8-14 Years Old
Verified date | December 2013 |
Source | BioGaia AB |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The present clinical trial will examine the use of L. reuteri Protectis in children with functional abdominal pain. The aim of the study is to evaluate the use of L. reuteri Protectis on pain (severity and frequency) in children of 8-14 years old and with diagnosis of functional abdominal pain (FAP).
Status | Terminated |
Enrollment | 9 |
Est. completion date | April 2013 |
Est. primary completion date | April 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 8 Years to 14 Years |
Eligibility | Inclusion Criteria: - FAP (Functional Abdominal Pain) according to Rome III criteria for - Child/Adolescent (Rasquin, 2006); - 1 or more abdominal pain episodes per week over the past 8 weeks; - Informed consent by study participant and at least one parent / legal guardian; - Age 8-14 years; - Pain severity at study entry must be at least 40 mm on a 100 mm VAS scale; - Ability to understand and comply with the requirements of the trial; - Stated availability throughout the study period. Exclusion Criteria: - Chronic illness; - Surgery of Gastrointestinal tract; - Any organic symptoms and/or clinical signs of disorder or disease other than FAP; - Weight loss of 5% or more in body weight over the preceding 3 months; - Any abnormal result of laboratory assays, also including screening for celiac disease, lactose intolerance; - Exposure to any drug or medication (antidepressants, SSRIs, laxatives) in the past 3 months or regular use of this medication; - Exposure to probiotics or antibiotics within 4 weeks prior to study; subjects can be included following a wash-out period of 4 weeks. - Participation in other clinical trials in the past 3 months; - Subjects with anemia; - Subjects with special dietary needs |
Country | Name | City | State |
---|---|---|---|
Italy | AO Niguarda Ca' granda | Milan | |
Italy | AO "San Paolo" | Milano |
Lead Sponsor | Collaborator |
---|---|
BioGaia AB | Sprim CRO, Italia |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary endpoint | Pain frequency measured by a subject diary, in the L. reuteri Protectis group and the placebo group, expressed as area under the pain-frequency curve and comparing L. reuteri Protectis vs. placebo over the 4-week supplementation period. | 4 weeks | |
Secondary | Secondary endpoint | Pain frequency measured by subject diary and expressed as area under the curve, comparing L. reuteri protectis vs. placebo over the initial 2 weeks of the supplementation period. Pain severity measured by the face score system by Wong-Baker at day 14, 28 and 56 (follow up) vs baseline, and area under the curve for weeks 1-4 and 1-2. Treatment success, defined as = 50% reduction in pain frequency in weeks 1-4. Reduction in days of absence from school. Parents' absence from work. Need of rescue medication. | 56 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04682860 -
Management of Abdominal Pain in Acute Gastroenteritis Patients With Hyoscine Butylbromide
|
Phase 4 | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Completed |
NCT02923245 -
POCUS Assessment of Bladder Fullness for Girls Awaiting Radiology-Performed Transabdominal Pelvic Ultrasound
|
N/A | |
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
Completed |
NCT02547857 -
Transvaginal Pelvic Ultrasound in the ED
|
N/A | |
Completed |
NCT02676232 -
DARWeb: an Online Psychosocial Intervention for Children With Recurrent Abdominal Pain and Their Families.
|
N/A | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Recruiting |
NCT00209807 -
Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
|
Phase 4 | |
Terminated |
NCT01410071 -
Evaluation of Gastrointestinal Symptoms and Quality of Life in Patients With Sphincter of Oddi Dysfunction
|
N/A | |
Terminated |
NCT01736280 -
Evaluating and Treating Potential Research Participants With Digestive Disorders
|
N/A | |
Enrolling by invitation |
NCT04104867 -
Effectiveness of Prokinetic Agents in Improving Abdominal Discomfort at Colonoscopy
|
N/A | |
Completed |
NCT03574727 -
Abdominal Cutaneous Nerve Entrapment Syndrome
|
||
Completed |
NCT04614649 -
Right Iliac Fossa Treatment-Turkey Audit
|
||
Completed |
NCT05438654 -
Improvement of Diagnostic Approach Using PoCUS for Right Upper Quadrant Abdominal Pain
|
N/A | |
Completed |
NCT06423586 -
Effect of Lecithin-based Curcuma and Boswellia on Post-acute COVID-19 IBS
|
N/A | |
Completed |
NCT03558009 -
Epidemiological Analysis for Hereditary Angioedema Disease
|
||
Terminated |
NCT03148288 -
Vitamin D Supplementation in IBS
|
N/A | |
Completed |
NCT03708874 -
Pain Management of Emergency Laparoscopic Cholecystectomy in Patients With Acute Cholecystitis
|
||
Withdrawn |
NCT04408872 -
EUS vs EGD in Emergency Room Patients Referred for EGD
|
N/A | |
Recruiting |
NCT02594774 -
Efficacy of Osteopathic Treatment in Function Abdominal Pain in Children and Adolescents
|
N/A |